Genomic analysis of 733 HER2+breast cancers identifies recurrent pathways alterations associated with anti-HER2 resistance and new therapeutic vulnerabilities

被引：0
|
作者：
Ferraro, Emanuela
Smith, Alison
Safonov, Anton
De Lara, Paulino Tallon
Bernado, Cristina
Lahuerta, Enrique J. Arenas
Arribas, Joaquin
Solit, David
Reis-Filho, Jorge S.
Rosen, Neal
Norton, Larry
Modi, Shanu
Robson, Mark E.
Dang, Chau T.
Curigliano, Giuseppe
Chandarlapaty, Sarat
Razavi, Pedram
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-GS3-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS3-03
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+breast cancer
    Gagliato, Debora de Melo
    Fontes Jardim, Denis Leonardo
    Pereira Marchesi, Mario Sergio
    Hortobagyi, Gabriel N.
    ONCOTARGET, 2016, 7 (39) : 64431 - 64446
  • [2] HER2+breast cancers evade anti-HER2 therapy via a switch in driver pathway
    Smith, Alison E.
    Ferraro, Emanuela
    Safonov, Anton
    Morales, Cristina Bernado
    Lahuerta, Enrique J. Arenas
    Li, Qing
    Kulick, Amanda
    Ross, Dara
    Solit, David B.
    de Stanchina, Elisa
    Reis-Filho, Jorge
    Rosen, Neal
    Arribas, Joaquin
    Razavi, Pedram
    Chandarlapaty, Sarat
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [3] Mevalonate pathway mediates acquired anti-HER2 treatment resistance in HER2+breast cancer
    Hu, Huizhong
    Simon, Lukas
    Qin, Lanfang
    Nardone, Agostina
    Shaw, Chad
    Chamness, Gary
    Heiser, Laura
    Wang, Nicholas
    Gray, Joe W.
    Osborne, C. Kent
    Schiff, Rachel
    CANCER RESEARCH, 2015, 75
  • [4] Drug resistance mechanisms create targetable proteostatic vulnerabilities in Her2+breast cancers
    Singh, Navneet
    Romick-Rosendale, Lindsey
    Watanabe-Chailland, Miki
    Vinnedge, Lisa M. Privette
    Komurov, Kakajan
    PLOS ONE, 2022, 17 (12):
  • [5] Targeting the mevalonate pathway in HER2+breast cancer to overcome resistance and enhance anti-HER2 therapy efficacy
    Sethunath, Vidyalakshmi
    Hu, Huizhong
    DeAngelis, Carmine
    Veeraraghavan, Jamunarani
    Qin, Lanfang
    Shea, Martin
    Mitchell, Tamika
    Nanda, Sarmistha
    Pereira, Resel
    Hilsenbeck, Susan G.
    Rimawi, Mothaffar F.
    Osborne, Kent C.
    Schiff, Rachel
    CANCER RESEARCH, 2019, 79 (13)
  • [6] Integrative analysis of multiomics tumor profiles identifies pathways associated with resistance to anti-HER2 therapy in early stage breast cancer
    Singh, Salendra
    Gilmore, Hannah
    Abu-Khalaf, Maysa
    Somlo, George
    Sikov, William
    Harris, Lyndsay
    Varadan, Vinay
    CANCER RESEARCH, 2017, 77
  • [7] Resistance to anti-HER2 therapy in HER2+breast cancer is mediated by genomic alterations that switch pathway dependence from PI3K/AKT to RAS/MAPK
    Smith, Alison E.
    Chandarlapaty, Sarat
    CANCER RESEARCH, 2020, 80 (16)
  • [8] Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer
    Madrid-Paredes, Adela
    Canadas-Garre, Marisa
    Sanchez-Pozo, Antonio
    Angel Calleja-Hernandez, Miguel
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 153 (03) : 493 - 505
  • [9] Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer
    Adela Madrid-Paredes
    Marisa Cañadas-Garre
    Antonio Sánchez-Pozo
    Miguel Ángel Calleja-Hernández
    Breast Cancer Research and Treatment, 2015, 153 : 493 - 505
  • [10] Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+breast cancer
    Liu, Yunhua
    He, Xiaoming
    Lu, Xiongbin
    Zhang, Xinna
    CANCER RESEARCH, 2019, 79 (13)
12345